孕激素受体在诱导的多能干细胞 (iPSC) 中构成性表达
Michele Manganelli1, Elena Laura Mazzoldi1, Rosalba Monica Ferraro1
1Angelo Nocivelli Institute for Molecular Medicine, Department of Molecular and Translational Medicine, University of Brescia, ASST Spedali Civili, 25123, Brescia, Italy.
Stem cell reviews and reports
|August 21, 2024
概括
诱导多能干细胞 (iPSCs) 在重新编程后显示孕激素受体 (PR) 表达. 没有检测到雌激素受体α (ERα),这表明PR没有检测到.
科学领域:
- 干细胞生物学 干细胞生物学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 激素受体,如雌激素受体α (ERα) 和孕激素受体 (PR),调节关键的生理过程.
- 了解诱导多能干细胞 (iPSC) 中的激素受体表达对于3D疾病建模和再生医学等应用至关重要.
- 纳入激素受体数据可以增强基于iPSC的疾病建模和有机体发育中的分子事件重复.
研究的目的:
- 研究来自不同细胞类型和重编程方法的iPSC中ERα和PR的表达模式.
- 为了确定细胞重编程是否影响这些关键激素受体的表达.
主要方法:
- 通过使用各种重编程技术,从CD34+原生细胞和皮肤纤维细胞生成了四个不同的iPSC系.
- 通过RT-qPCR量化ERα和PRmRNA表达,将iPSC和亲细胞与阳性对照细胞进行比较 (MCF7).
- 使用免疫光 (IF) 染色检测出蛋白质表达,并通过流细胞计量量化表达PR和ERα的细胞群.
主要成果:
- 与MCF7对照组相比,ERα和PR mRNA水平在iPSC和纤维细胞中显著下调.
- 免疫光检测到PR蛋白表达在所有测试的iPSC线路,但ERα蛋白不能检测到.
- 流细胞测量显示,大约65%的iPSC表达了PR,与造血干细胞/原生细胞 (HSPC) 和纤维细胞相比,显示了100%的折叠增加;ERα仍然未表达.
结论:
- 细胞重新编程成iPSC导致孕激素受体 (PR) 的表达.
- 在这些重新编程的iPSC中,雌激素受体α (ERα) 表达显著缺席.
- 这些发现为iPSCs的荷尔蒙环境提供了新的见解,影响了它们在疾病建模和再生疗法中的使用.
关键词:
CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34 CD34不同化的差异化雌激素受体的受体是什么纤维细胞细胞.诱导多能干细胞 (iPSCs) 是一种干细胞.孕激素受体是什么? 孕激素受体是什么?更多相关视频
相关概念视频
Induced Pluripotent Stem Cells
22.0K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
22.0K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Chromatin Modification in iPS Cells
1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K


